Market closedNon-fractional
KemPharm/ZVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About KemPharm
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Ticker
ZVRA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Celebration, United States
Employees
67
Website
zevra.com
KemPharm Metrics
BasicAdvanced
$178M
Market cap
-
P/E ratio
-$1.33
EPS
1.87
Beta
-
Dividend rate
Price and volume
Market cap
$178M
Beta
1.87
Financial strength
Current ratio
2.103
Quick ratio
2.04
Long term debt to equity
89.522
Total debt to equity
90.717
Interest coverage (TTM)
-27.88%
Management effectiveness
Return on assets (TTM)
-27.75%
Return on equity (TTM)
-82.27%
Valuation
Price to revenue (TTM)
5.731
Price to book
3.64
Price to tangible book (TTM)
-7.53
Price to free cash flow (TTM)
-3.458
Growth
Revenue change (TTM)
195.67%
Earnings per share change (TTM)
-11.10%
3-year revenue growth
5.92%
3-year earnings per share growth
-42.09%
What the Analysts think about KemPharm
Analyst Ratings
Majority rating from 6 analysts.
KemPharm Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.4M
-74.24%
Net income
-$17M
9.93%
Profit margin
-488.23%
326.81%
KemPharm Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.40
-$0.40
-$0.40
-
Expected
-$0.34
-$0.30
-$0.27
-$0.48
-$0.42
Surprise
-56.31%
34.45%
49.07%
-16.32%
-
KemPharm News
AllArticlesVideos
Zevra Therapeutics Expands Executive Leadership Team
GlobeNewsWire·2 weeks ago
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
PRNewsWire·3 weeks ago
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for KemPharm stock?
KemPharm (ZVRA) has a market cap of $178M as of July 06, 2024.
What is the P/E ratio for KemPharm stock?
The price to earnings (P/E) ratio for KemPharm (ZVRA) stock is 0 as of July 06, 2024.
Does KemPharm stock pay dividends?
No, KemPharm (ZVRA) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next KemPharm dividend payment date?
KemPharm (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for KemPharm?
KemPharm (ZVRA) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell KemPharm stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.